Predictive Oncology Inc. POAI Archives - Page 8 of 19

WednesdayNov 11, 2020 2:12 pm

Predictive Oncology (NASDAQ: POAI) CEO Joins NNW Podcast to Discuss Company’s Prospects; Provides Update on POAI Subsidiaries

Predictive Oncology CEO Carl Schwartz featured on NNW’s podcast to discuss the company’s prospects Schwartz elaborated on company’s various divisions, affirming that POAI had begun to see revenue trends stabilize, cash burn rates decline TumorGenesis received overwhelmingly positive feedback on its initial product launches, with plans to extend its technological prowess to address other oncological segments Soluble Biotech, which announced its first major contract in August, is expected to reveal news of second order win in near future Schwartz touched upon POAI’s Helomics business, stating his belief that division could soon transition towards monetizing its unique and one-of-a-kind asset portfolio…

FridayNov 06, 2020 1:37 pm

Predictive Oncology (NASDAQ: POAI) Subsidiary’s HSC Technology Optimization Solution Offers Unparalleled Results, Benefits

POAI subsidiary Soluble Biotech’s optimization solution shaves time and cost off of traditional options offered by competition Results garnered from company’s HSC optimization are unparalleled in field Soluble Biotech lands first major contract, signifying major company milestone Offering a proprietary automated High Throughput Self-Interaction Chromatography(TM) (“HSC”) Technology Platform, Predictive Oncology (NASDAQ: POAI) provides biomedical and pharmaceutical companies with superior options never before available. A knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, POAI, through its subsidiary Soluble Biotech, delivers a solution that reduces the cost, time and manpower needed to optimize therapeutic formulations. HSC…

TuesdayOct 27, 2020 12:31 pm

QualityStocksNewsBreaks – Predictive Oncology (NASDAQ: POAI) CEO Provides Company Updates on Exclusive NNW Audio Interview

Predictive Oncology (NASDAQ: POAI) CEO Carl Schwartz was featured in a recent NetworkNewsWire (“NNW”) audio interview. During the interview, Schwartz provided updates on the company’s subsidiaries, noted recent company milestones and outlined near-term goals. POAI, a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has four wholly owned subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Schwartz focused the discussion on these companies, offering brief insight into the operations of Skyline Medical and noting that the purpose of TumorGenesis was to develop a lab media to replace rats and mice in the scientific industries…

WednesdayOct 21, 2020 9:27 am

Predictive Oncology Inc. (NASDAQ: POAI) Industry Leader in Growing Precision Medicine Market

Recent study reports CAGR of 9.7% in precision medicine space. Predictive Oncology focused on use of data, artificial intelligence to develop personalized cancer therapies. One of POAI’s primary projects is building multi-omic predictive models of tumor drug response A recent study of the global precision medicine market indicates a bright future for the industry, especially for U.S.-based companies focusing on cancer research, such as Predictive Oncology Inc. (NASDAQ: POAI). The study reported a CAGR of 9.7% in the sector, with North America dominating the market and oncology expected to hold the highest market. “Precision medicine, a combination of molecular biology…

ThursdayOct 15, 2020 1:57 pm

QualityStocksNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Soluble Biotech Looks to Bright Future with First Contract on the Books

Predictive Oncology (NASDAQ: POAI)’s Soluble Biotech division has finalized its first substantial contract with a pharmaceutical company since its acquisition by POAI earlier this year (https://ibn.fm/gXjd2). Soluble Biotech is a provider of stable and soluble formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes. Under the contract, Soluble Biotech will provide its expertise in protein expression and solubility studies. A recent article discussing this quotes Soluble Biotech founder Dr. Larry DeLucas. “Our first contract is a major milestone and validates our recent move into a new, larger facility,” Dr. DeLucas stated. “We quadrupled our laboratory and…

TuesdayOct 13, 2020 1:20 pm

Predictive Oncology Inc. (NASDAQ: POAI) CEO Schwartz Pens Letter to Shareholders, Elaborates on Ongoing Company Developments

Predictive Oncology’s CEO Carl Schwartz published open letter to company’s shareholders Schwartz elaborated on various developments within each of POAI’s divisions, has reiterated his optimism on company’s operations going forward CEO also revealed that company’s revenue trends have stabilized and are now on upward trend with cash burn beginning to decline Company also revealed its ability to access over $10 million in undrawn equity lines of credit Carl Schwartz, the CEO of Predictive Oncology (NASDAQ: POAI), a knowledge-driven medicine company that focuses on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug discovery, has recently published a…

TuesdayOct 06, 2020 12:51 pm

QualityStocksNewsBreaks – Predictive Oncology (NASDAQ: POAI) Shareholder Letter Provides Company Update, Status of Subsidiaries

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has released a shareholder letter providing a review of where POAI “stands as of today.” The letter noted that, despite a decline of stock price over the past few weeks, the company’s cash burn is stable and even trending down, and revenues are stable and trending upward. The letter notes that POAI has adequate cash for operation, as well as ability to utilize an equity line of credit of more than $10 million. The letter also provides an update on the…

FridayOct 02, 2020 1:07 pm

QualityStocksNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Helomics CIO Discusses Convergence of AI, Data and Biology on DojoLIVE!

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, was featured in a recent article discussing the appearance of one of its executives, Helomics CIO Mark Collins, PhD, on DojoLIVE! (https://ibn.fm/Y9fBZ). POAI’s Helomics subsidiary applies AI to its rich data gathered from more than 150,000 tumors in an effort to personalize cancer therapies and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Collins addressed this powerful work and his longtime passion during the interview titled, “Can We Cure Cancer with Artificial Intelligence?” “The last 20 years of…

TuesdaySep 29, 2020 1:28 pm

Predictive Oncology Inc. (NASDAQ: POAI) Set to Capitalize on Increased AI Usage within Oncological Treatments

Predictive Oncology develops AI-solutions designed to assist clinicians in formulating personalized treatment plans for oncological patients Artificial Intelligence is being increasingly used to help understand and accurately predict how drug therapies can interact with specific patients POAI’s TumorGenesis subsidiary is also creating laboratory-grown tumors to help clinicians and researchers to better test therapies Predictive Oncology (NASDAQ: POAI), a knowledge-driven precision medicine company that focuses on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug discovery, is set to play a key role as the integration of AI technology within cancer care continues to improve the accuracy and…

ThursdaySep 24, 2020 2:08 pm

Predictive Oncology Inc.’s (NASDAQ: POAI) Soluble Biotech Inks Major Contract; Skyline Medical Seals STREAMWAY Deal

POAI’s Soluble Biotech announces first substantial contract with pharmaceutical company since acquisition Founder calls contract “major milestone,” validation of move into new facility POAI’s Skyline Medical sells eight proprietary STREAMWAY(R) systems to Virginia-based hospital organization Soluble Biotech, a division of Predictive Oncology (NASDAQ: POAI), has finalized its first substantial contract with a pharmaceutical company since being acquired by POAI earlier this year (https://ibn.fm/gXjd2). Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes. The contract calls for Soluble Biotech’s expertise in protein expression and solubility studies. “Our first…

Site Search

Company Search

Tag: Predictive Oncology Inc. POAI